Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatement of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count <= 10x10^9/L)	1
Treatement of patients with relapsed or refractory APL after ATRA/chemotherapy	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide